In February, Plus Therapeutics was awarded a winner of the Buzz of BIO awards. Each year, ten biotech companies are nominated in three categories. Plus Therapeutics won in the Public Therapeutic Biotech category.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Plus Therapeutics, Inc. (NASDAQ: PSTV) is ending 2022 on a high note after a year of significant clinical progress. Plus Therapeutics is a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers with a focus in central nervous system diseases.
Plus Therapeutics aims to revolutionize the world of cancer radiation by using targeted radiotherapeutics and leveraging novel drugs and technologies. The company’s method is designed to deliver a single, safe and effective dose of radiation that is administered directly to the tumor. By doing so, the patient is able to preserve normal cell and tissue functionality and potentially add years to patients’ lives.
The company is currently undergoing two clinical trials using rhenium (186Re) obisbemeda. In both trials, ReSPECT-GBM and ReSPECT-LM, the Company recently announced that rhenium (186Re) obisbemeda has, thus far, been shown to be both feasible and safe across a range of doses and a variety of delivery parameters. The company is looking forward to working with the FDA to further the advancement of its research, trials and therapeutic development with its novel ReSPECT-GBM and ReSPECT-LM drugs.
The third quarter of 2022 was a period of significant progress for Plus Therapeutics, highlighted by the achievement of several key developmental milestones. Plus Therapeutics announced that through the combination of current cash, committed grant funding, and discretionary capital sources the company has secured its cash runway through 2025.
As of September 30, 2022, the company’s cash balance was $20.3 million, which is up from $18.4 million at December 31, 2021. In September the company was awarded a $17.6 million grant from the Cancer Prevention & Research Institute of Texas to support the development of new drugs to help treat leptomeningeal metastases.
In 2022, the company presented at numerous high-profile events to spread awareness about its innovative technological advancements in the oncological space. Plus Therapeutics presented at the HC Wainwright 24th Annual Global Investment Conference, as well as high-profile global scientific meetings including the European Society for Medical Oncology Congress the European Association of Nuclear Medicine Congress, and the Society for Neuro-Oncology to name a few.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Photo by Ani Kolleshi on Unsplash
